FIELD: medicine, phthisiology.
SUBSTANCE: one should introduce rifampicin in liposomal form, at daily dosage containing 0.1-100.0 mg rifampicin and 4.0-700.0 mg phospholipids depending upon the size of affected organ right into the above-mentioned affected organ during, at least, 4 wk. The present innovation enables to increase the frequency of abacylation, close cavernae and decrease infiltrative and focal alterations in tuberculosis-suffering patients, with multiple medicinal resistance, among them.
EFFECT: higher efficiency of therapy.
11 cl, 5 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PULMONARY TUBERCULOSIS TREATMENT METHOD | 2002 |
|
RU2195313C1 |
| METHOD FOR TREATMENT OF PULMONARY TUBERCULOSIS MULTIPLE DRUG-RESISTANCE OF TUBERCULOSIS MYCOBACTERIA | 2018 |
|
RU2687743C1 |
| METHOD FOR TREATMENT OF PULMONARY ORGANS TUBERCULOSIS | 2005 |
|
RU2299068C2 |
| METHOD FOR TREATING PULMONARY TUBERCULOSIS | 2004 |
|
RU2253460C1 |
| METHOD FOR TREATING DIFFERENT FORMS OF PULMONARY TUBERCULOSIS, RESISTANT TO ANTITUBERCULAR CHEMOTHERAPY, AMONG THEM | 2001 |
|
RU2197984C1 |
| COMBINED ANTITUBERCULOUS DRUG AND METHOD FOR PREPARING THEREOF | 2008 |
|
RU2431487C2 |
| METHOD FOR TREATMENT OF PATIENTS WITH ENCYSTED TUBERCULOSIS PLEURITIS | 2003 |
|
RU2239437C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH DESTRUCTIVE FORMS OF PULMONARY TUBERCULOSIS | 2007 |
|
RU2347575C1 |
| ANTITUBECULOUS-CAUSED MEDICAMENTOUS POLYNEUROPATHY APPROACH | 2007 |
|
RU2353360C2 |
| METHOD OF TREATING PATIENTS WITH PULMONARY TUBERCULOSIS WITH ACCOMPANYING NON-SPECIFIC BRONCHITES | 2013 |
|
RU2526121C1 |
